Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 September 2021 | Story Leonie Bolleurs | Photo Supplied
Prince Matova, a PhD student in the Department of Plant Sciences, has been working on breeding a maize that can resist the fall armyworm (FAW) – a maize-eating pest. Later in September, he will receive the Young Scientist Award from the Plant Mutation Breeding Division of the International Atomic Energy Agency (IAEA) and the Food and Agriculture Organisation of the United Nations (FAO).

Prince Matova, a PhD student in Plant Breeding at the University of the Free State (UFS), received the Young Scientist Award from the Joint Food and Agriculture Organisation of the United Nations (FAO)/International Atomic Energy Agency (IAEA) Division of Nuclear Techniques in Food and Agriculture for excellence in plant mutation breeding.

The IAEA Director-General, Mr Rafael Mariano Grossi, will officially announce the award at the 65th regular session of the IAEA General Conference that will take place later in September this year.

The award is given to scientists younger than 40, who have made a significant contribution and impact in the field of mutation breeding.

Matova, a researcher, research and agronomy manager, and maize and legumes breeder at Mukushi Seeds (Pvt) Ltd in Harare, Zimbabwe, says: “People have seen the little work that I have done, and they were happy with it. That makes me happy too.”

Other contributions

In the ten years collaborating with the IAEA, practising mutation breeding, Matova – who believes innovative thinking and self-motivation to be contributing factors to a successful scientist – has also been recognised for other outstanding contributions. These include the release of a cowpea mutant variety in 2017 and its wide dissemination across Zimbabwe, as well as the modernisation of the maize and cowpea national breeding programmes. He has also contributed two publications and appeared twice at IAEA Plant Mutation Breeding symposia. Furthermore, Matova has trained other scientists and fellows across Africa and collaborated with centres of excellence in plant breeding, research, and development.

Growing up, he never guessed that he would one day become an agricultural scientist. Matova was, however, very good at biology and believes that this is one of the reasons why he ended up in crop science. “I am enjoying every moment of it. I love innovativeness and inventions and I view hybrid maize variety development as the greatest innovation in plant breeding. Working for Mukushi Seeds is inspiring; I have a young and dedicated team and the environment allows me to explore my full potential.”

“I feel science solves problems and every day as I do my breeding work, I have this desire to achieve greatness by developing a super maize hybrid,” he says.

Displaying excellence

For the past three to four years, Matova has been working to breed maize varieties that can resist fall armyworm (FAW) – a maize-eating pest. He says the pest has caused significant maize crop yield and economic losses across Africa.

More than 300 million smallholder farmers across sub-Saharan Africa rely on maize for food and livelihoods. “These farmers have limited capacities to control the pest. They are using insecticides, which we have seen to effectively provide immediate control of the pest.” However, these pesticides have environmental and health issues. “It is against this background that we, as plant breeders, felt it was important to develop varieties that are resistant to the pest. It is a more environmentally friendly, less expensive, and more sustainable solution,” explains Matova.
In his research, he evaluated the breeding potential of exotic FAW-resistant donor lines with local lines. He also investigated the resistance response and stability of local cultivars and inbred lines against FAW. 

While working at the Zimbabwean Department of Research and Specialist Services (DR&SS), Matova collaborated with the International Maize and Wheat Improvement Center (CIMMYT), the University of Zimbabwe, the UFS, and the IAEA to look into the possibility of using mutation breeding in maize crop improvement, with the intention to enhance FAW-resistance in maize genotypes.

He introgressed FAW resistance into the elite breeding materials at both DR&SS and Mukushi Seeds, where he is currently working. Matova believes that although FAW resistance is currently a nice-to-have trait, going forward, all maize varieties released should have a baseline resistance to FAW.

Ultimately, his work generated important information that can guide research and maize breeding for FAW resistance in Southern Africa. All this information is free for researchers to use for the betterment of Africa and the world.

Inspired by greatness

There are a number of people in the industry and academia who have inspired Matova. The list includes Dr Cosmos Magorokosho (CIMMYT), Prof Hussein Shimelis (University of KwaZulu-Natal), Dr Fatma Sarsu (IAEA), Dr Marilyn Warburton (Agricultural Research Service in the United States Department of Agriculture), Dr Amsal Terekegne (ZAMSEED), and Dr John MacRobert (Mukushi Seeds). They all contributed in one way or another to influence Matova in a positive way towards becoming the passionate scientist he is today.

Besides this list of prominent names, Matova says that he was more recently also motivated and encouraged by his PhD supervisor and mentor, Prof Maryke Labuschagne, Professor in Plant Sciences at the UFS. “She is a very special person doing a wonderful job. Prof Labuschagne is kind, thorough, hardworking, and a good mentor,” he states.

Prof Labuschagne is very proud of Matova for receiving this award. “He has been working really hard, and this is a wonderful recognition of the time and effort that he has invested in his research,” she says.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept